Biological properties of a newly isolated bacteriophage (NL1) that infects Escherichia coli O157:H7 strain

Öz

Escherichia coli O157: H7 strain was used as the standard strain for bacteriophages isolated from polluted environmental foci and animal waste-contaminated waters, and some of the enteroinvasive Escherichia coli strains previously isolated from sporadic cases were used to determine the host diversity of phages. The physiological properties of bacteriophages specific to Escherichia coli O157:H7, designated Escherichiaphage NL1, were studied. After the isolation step, bacteriophages were purified and their titer was increased. Cross-antigenic properties of the hosts were investigated with Escherichia phage NL1 phage. One-step growth curve parameters such as adsorption time of phages, latent period, burst size, multiplicity of infection value (MOI) were determined. Results showed that bacteriophage NL1 completely lysed the E.coli O157:H7 (RSKK 09007) and E.coli O:164 RSKK 324. In the study, the effects of phage NL1 only on E.coli O157:H7 were investigated. The calculated highest titer was determined as Optimal multiplycity of infection (2.16x108). It was determined that the latent period lasted for 20 minutes and the phage was reached the burst size at approximately 90 minutes.

Anahtar Kelimeler

• Esherichia coli O157:H7
• bacteriophages
• resistance
• enterobacteria
• biocontrol

Kaynakça

1. Alves, D.R., Gaudion, A., Bean, J.E., Perez, E. P., Arnot, T.C., Harper, D.R., Kot, W., Hansen, L.H., Enright, M.C., Jenkins, A.T. (2014). Combined use of bacteriophage K and a novel bacteriophage to reduce Staphylococcus aureus biofilm formation.
2. Appl. Environ. Microbiol., 80(21), 6694-703. https://doi.org/10.1128/AEM.01789-14 Bhan, M.K., Mahalanabis, D., Fontaine, O., Pierce, N.F. (1994). Clinical trials of improved oral rehydration salt formulations: a review. Bull World Health Organ, 72(6), 945-55. PMID: 7867142; PMCID: PMC2486731.
3. Boyd, E. F., Brüssow, H. (2002). Common themes among bacteriophage-encoded virulence factors and diversity among the bacteriophages involved. Trends in Microbiology,10 (11), 521-9. https://doi.org/10.1016/S0966-842X(02)02459-9
4. Bruttin, A., Brüssow, H. (2005). Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents. Chemother., 49 (7), 2874-8. https://doi.org/10.1128/AAC.49.7.2874-2878.2005
5. Chibani-Chennoufi, S., Bruttin, A., Dillmann, M. L., Brüssow, H. (2004). Phage-host interaction: an ecological perspective. J. Bacteriol., 186, 3677–3686. https://doi.org/10.1128/JB.186.12.3677-3686.2004
6. Chkonia, I., et al. (2012). Antibacterial-antifungal natural composite for dental use. Bacteriophages and Probiotics-Alternative to Antibiotics Cogress, July 1-4, Tbilisi, Georgia.
7. Clokie, M.R.J., Kropinski, A.M. (2009). Bacteriophages Methods and Protocols. Springer Protocols. Humana Press. New York, USA.
8. Donjacour, A., Paros, M. (2012). Bacterophage prevention and therapy for coliform mastisis. Bacteriophages and Probiotics-Alternative to Antibiotics Cogress, July 1-4, Tbilisi, Georgia.

9. Donlan, R.M. (2009). Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol., 17(2), 66-72. https://doi.org/10.1016/j.tim.2008.11.002
10. Endersen, E., et al. (2012). Isolation and characterization of six novel Mycobacteriophages and ınvestigation of their antimicrobial potential in milk. Bacteriophages and Probiotics- Alternative to Antibiotics Cogress, July 1-4,Tbilisi, Georgia.
11. Goodridge, L., Gallaccio, A., Griffiths, M. W. (2003). Morphological, host range, and genetic characterization of two coliphages. Appl. Environ. Microbiol., 69, 5364–5371. https://doi.org/10.1128/AEM.69.9.5364-5371.2003
12. Kim, J. W., Kathariou, S. (2009). Temperature-dependent phage resistance in Listeria monocytogenes epidemic clone II strains. An. Soc. Microbiol., 75 (8), 2433-2438. https://doi.org/10.1128/AEM.02480-08
13. Kirby, A.E. (2012). Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS One, 7 (11), e51017. https://doi.org/10.1371/journal.pone.0051017
14. Kudva, I. T., Jelacic, S., Tarr, P. I., Youderian, P., Hovde, C. J. (1999). Biocontrol of Escherichia coli O157 with O157- specific bacteriophages, Appl. Environ. Microbiol., 65, 3767–3773. https://doi.org/10.1128/AEM.65.9.3767-3773.1999
15. Li, S., Deng, R., Zhang, S., Zhang, Z., Liang, K., Zhang, J. (2016). Isolation and biological characteristics of bacteriophage of an antibiotic-resistant Escherichia coli strain. Agricultural science and technology, 17(12), 2692-2695.
16. Lin L., Han J., Ji X., Hong W., Huang L., Wei Y. (2011). Isolation and characterization of a new bacteriophage MMP17 from Meiothermus. Extremophiles, 15, 253–258 https://doi.org/10.1007/s00792-010-0354-z
17. Manohar, P., Nachimuthu, R., Lopes, B.S. (2018). The therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model. BMC Microbiol., 18, 97. https://doi.org/10.1186/s12866-018-1234-4
18. Manohar, P., Tamhankar, A. J., Lundborg,C. S., Nachimuthu, R. (2019). Therapeutic characterization and efficacy of bacteriophage cocktails ınfecting Escherichia coli, Klebsiella pneumoniae, and Enterobacter Species. Frontiers in Microbiology, 10:574. https://doi.org/10.3389/fmicb.2019.00574
19. Ministry of Health and Welfare, Japan: JapanThe guideline on the treatment of O157 infection for primary and secondary medical facilities (The Research Group on Diagnosis and Treatment of Enterohemorrhagic Escherichia coli Infection; group leader, Yoshifumi Takeda).Jpn. J. Bacteriol.51 (1996) 1096-1098 (In Japanese.)
20. Nádia, V., Cristiana, O., Vânia, J., Tatiana, B., Carla, P., Catarina, M., Adelaide, A. (2017). Effects of single and combined use of bacteriophages and antibiotics to inactivate Escherichia coli. Virus Research, 240, 8-17. https://doi.org/10.1016/j.virusres.2017.07.015
21. O’Brien, A. D., Tesh, V. L., Donohue-Rolfe, A., Jachson, M. P., Olsnes, S., Sandrig, K., Lindberg, A. A., Keusch, G. T. (1992). Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. In: Sansonetti P.J. (eds) Pathogenesis of shigellosis. Current Topics in Microbiology and Immunology, Vol 180. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77238-2_4
22. O’Flynn, G., Ross, R. P., Fitzgerald, G. F., Coffey, A. (2004). Evaluation of a cocktail of three bacteriophages for biocontrol of Escherichia coli O157 : H7. Appl. Environ. Microbiol., 70, 3417–3424. https://doi.org/10.1128/AEM.70.6.3417-3424.2004
23. Polycaprolactone film functionalized with bacteriophage T4 promotes antibacterial activity of food packaging toward Escherichia coli. Food Chemistry, 346, 128883. https://doi.org/10.1016/j.foodchem.2020.128883
24. Pouillot, F., Gabard, J. (2012). Efficacy of phage therapy in experimental sepsis and meningitis coused by O25b:H4-ST131 E.coli strain producing CTX-M-15. Bacteriophages and Probiotics- Alternative to Antibiotics Cogress, July 1-4, Tbilisi, Georgia.
25. Ribeiro, K., Ribeiro, C., Dias, R. S., Cardoso, S. A., de Paula, S. O., Zanuncio, J. C., Oliveira, L. L. (2018). Bacteriophage ısolated from sewage eliminates and prevents the establishment of Escherichia coli biofilm. Advanced Pharmaceutical Bulletin, 8(1), 85–95. https://doi.org/10.15171/apb.2018.011
26. Savarino, S. J., Hall, E. R., Bassily, S. (2002). Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr. Infect. Dis., 21, 322–330. https://doi.org/10.1097/00006454-200204000-00012
27. Sulakvelidze, A., Alavidze, Z., Morris, J.G. (2001). Bacteriophage therapy. Antimicrobial Agents and Chemotetherapy, 45 (3), 649–659. https://doi.org/10.1128/AAC.45.3.649-659.2001
28. Viscardi, M., Perugini, A. G., Auriemma, C., Capuano, F., Morabito, S., Kim, K., Loessner, M. J., Lovane, G. (2008). Isolation and characterisation of two novel coliphages with high potential to control antibiotic-resistant pathogenic Escherichia coli (EHEC and EPEC), International Journal of Antimicrobial Agents, 31 (2), 152-157. https://doi.org/10.1016/j.ijantimicag.2007.09.007
29. Walterspiel, J.N., Ashkenazi, S., Morrow, A.L., Cleary, T.G. (1992). Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection, 20(1), 25-9. https://doi.org/10.1007/BF01704889
30. Zhang, Q.G., Buckling, A. (2012). Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. Evol. Appl., 5, 575-582. https://doi.org/10.1111/j.1752-4571.2011.00236.x